Loading…

Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis – 2012 Curt Richter Award Winner

Summary Low birthweight, a marker of an adverse in utero environment, is associated with cardiometabolic disease and brain disorders in adulthood. The adaptive changes made by the fetus in response to the intra-uterine environment result in permanent changes in physiology, structure and metabolism,...

Full description

Saved in:
Bibliographic Details
Published in:Psychoneuroendocrinology 2013-01, Vol.38 (1), p.1-11
Main Author: Reynolds, Rebecca M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c490t-13cafec02d73d166c83f27ed89ba994d481e690fcb4a097d620a4936405f3ffd3
cites cdi_FETCH-LOGICAL-c490t-13cafec02d73d166c83f27ed89ba994d481e690fcb4a097d620a4936405f3ffd3
container_end_page 11
container_issue 1
container_start_page 1
container_title Psychoneuroendocrinology
container_volume 38
creator Reynolds, Rebecca M
description Summary Low birthweight, a marker of an adverse in utero environment, is associated with cardiometabolic disease and brain disorders in adulthood. The adaptive changes made by the fetus in response to the intra-uterine environment result in permanent changes in physiology, structure and metabolism, a phenomenon termed early life programming. One of the key hypotheses to explain programming, namely over exposure of the developing fetus to glucocorticoids, was proposed nearly two decades ago, following the observation that the fetus was protected from high glucocorticoid levels in the mother by the actions of the placental barrier enzyme, 11β-hydroxysteroid dehydrogenase, which converts active glucocorticoids into inactive products. Numerous mechanistic studies in animal models have been carried out to test this hypothesis using manipulations to increase maternal glucocorticoids. Overall, these have resulted in offspring of lower birthweight, with an activated hypothalamic–pituitary–adrenal (HPA) axis and an adverse metabolic profile and behavioural phenotype in adulthood. Altered glucocorticoid activity or action is a good candidate mechanism in humans to link low birthweight with cardiometabolic and brain disorders. We have carried out detailed studies in men and women showing that high levels of endogenous glucocorticoids, or treatment with exogenous glucocorticoids, is associated with an adverse metabolic profile, increased cardiovascular disease and altered mood and cognitive decline. Our laboratory carried out the first translational studies in humans to test the glucocorticoid hypothesis, firstly demonstrating in studies of adult men and women, that low birthweight was associated with high fasting cortisol levels. We went on to dissect the mechanisms underlying the high fasting cortisol, demonstrating activation of the HPA axis, with increased cortisol responses to stimulation with exogenous adrenocorticotrophin hormone, lack of habituation to the stress of venepuncture, and increased cortisol responses to psychosocial stress. We have developed new dynamic tests to dissect the mechanisms regulating HPA axis central negative feedback sensitivity in humans, and demonstrated that this may be altered in obesity, one component of the metabolic syndrome. There are now studies in humans demonstrating that high circulating levels of maternal cortisol during pregnancy correlate negatively with birthweight, suggesting that excess glucocorticoids can by-pass the
doi_str_mv 10.1016/j.psyneuen.2012.08.012
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1272746186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0306453012003034</els_id><sourcerecordid>1272746186</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-13cafec02d73d166c83f27ed89ba994d481e690fcb4a097d620a4936405f3ffd3</originalsourceid><addsrcrecordid>eNqFkrtuFDEUhi0EIkvgFSKXNDv4Fo9NgYhWEJAiIUEQpeW1z2S9zNqDPZOwHSU9b8iT4MkmFDRUv2V9_7kjdEJJQwmVL7bNUPYRJogNI5Q1RDVVHqAFVS1fci7JQ7QgnMilOOXkCD0pZUsIkUqyx-iIMa2VFmqBfp73k0su5TG4FDyG7w5KwTZ6PG4Ae7iGPg07iKPtccrhKsSCU4d9KGALvMSXN6lSznq4_R-hjCFe3Zo3-yFVLaHg3z9-4blOvJryiD8Gtxkh47Mbmz3-EmKE_BQ96mxf4NmdHqPPb99crt4tLz6cv1-dXSyd0GRcUu5sB44w33JPpXSKd6wFr_Taai28UBSkJp1bC0t06yUjVmguBTnteNd5foyeH-IOOX2barVmF4qDvrcR0lQMZS1rhaRKVlQeUJdTKRk6M-Sws3lvKDHzFszW3G_BzN0ZokyVajy5yzGtd-D_2u7HXoHXBwBqp9cBsikuQHTgQwY3Gp_C_3O8-ieE60MMzvZfYQ9lm6Yc6xwNNaV6zKf5FuZToIzUJxf8D_ows6Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1272746186</pqid></control><display><type>article</type><title>Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis – 2012 Curt Richter Award Winner</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Reynolds, Rebecca M</creator><creatorcontrib>Reynolds, Rebecca M</creatorcontrib><description>Summary Low birthweight, a marker of an adverse in utero environment, is associated with cardiometabolic disease and brain disorders in adulthood. The adaptive changes made by the fetus in response to the intra-uterine environment result in permanent changes in physiology, structure and metabolism, a phenomenon termed early life programming. One of the key hypotheses to explain programming, namely over exposure of the developing fetus to glucocorticoids, was proposed nearly two decades ago, following the observation that the fetus was protected from high glucocorticoid levels in the mother by the actions of the placental barrier enzyme, 11β-hydroxysteroid dehydrogenase, which converts active glucocorticoids into inactive products. Numerous mechanistic studies in animal models have been carried out to test this hypothesis using manipulations to increase maternal glucocorticoids. Overall, these have resulted in offspring of lower birthweight, with an activated hypothalamic–pituitary–adrenal (HPA) axis and an adverse metabolic profile and behavioural phenotype in adulthood. Altered glucocorticoid activity or action is a good candidate mechanism in humans to link low birthweight with cardiometabolic and brain disorders. We have carried out detailed studies in men and women showing that high levels of endogenous glucocorticoids, or treatment with exogenous glucocorticoids, is associated with an adverse metabolic profile, increased cardiovascular disease and altered mood and cognitive decline. Our laboratory carried out the first translational studies in humans to test the glucocorticoid hypothesis, firstly demonstrating in studies of adult men and women, that low birthweight was associated with high fasting cortisol levels. We went on to dissect the mechanisms underlying the high fasting cortisol, demonstrating activation of the HPA axis, with increased cortisol responses to stimulation with exogenous adrenocorticotrophin hormone, lack of habituation to the stress of venepuncture, and increased cortisol responses to psychosocial stress. We have developed new dynamic tests to dissect the mechanisms regulating HPA axis central negative feedback sensitivity in humans, and demonstrated that this may be altered in obesity, one component of the metabolic syndrome. There are now studies in humans demonstrating that high circulating levels of maternal cortisol during pregnancy correlate negatively with birthweight, suggesting that excess glucocorticoids can by-pass the placental barrier. Deficiencies in the barrier enzyme, potentially increasing fetal glucocorticoid exposure, can also arise in association with maternal stress, malnutrition and disease, and can be inhibited by consumption of liquorice, which contains glycyrrhizin, an HSD inhibitor. Importantly, studies in humans have now demonstrated that high maternal cortisol in pregnancy and/or inhibition of HSD2 are associated with programmed outcomes in childhood including higher blood pressure, behavioural disorders as well as altered brain structure. We are investigating this further, using novel magnetic resonance imaging techniques to study the developing fetal brain in utero. The translational studies in support of the glucocorticoid hypothesis, and demonstrating that glucocorticoids are both mediators and targets of programming, are exciting and raise the question of whether this information can be used to identify those individuals most at risk of later life disease. In a recent study we showed that alterations in DNA methylation at genes important in regulating cortisol levels, tissue glucocorticoid action, blood pressure and fetal growth, are present in adulthood in association with both early life parameters and cardiometabolic risk factors. These preliminary data add to the limited literature in humans indicating a persisting epigenetic link between early life events and subsequent disease risk. Such findings open novel avenues for further exploration of the contribution of glucocorticoids to later life disease.</description><identifier>ISSN: 0306-4530</identifier><identifier>EISSN: 1873-3360</identifier><identifier>DOI: 10.1016/j.psyneuen.2012.08.012</identifier><identifier>PMID: 22998948</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>11 beta -Hydroxysteroid dehydrogenase ; 11-beta-Hydroxysteroid Dehydrogenase Type 2 - antagonists &amp; inhibitors ; 11-beta-Hydroxysteroid Dehydrogenase Type 2 - physiology ; Adaptation, Physiological ; Adult ; Animal models ; Animals ; Awards and Prizes ; Birth weight ; Birthweight ; Brain ; Brain Diseases, Metabolic - embryology ; Brain Diseases, Metabolic - etiology ; Brain Diseases, Metabolic - physiopathology ; Cardiovascular Diseases - embryology ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - physiopathology ; Cognition Disorders - etiology ; Cognition Disorders - physiopathology ; Cognitive decline ; Cushing Syndrome - embryology ; Cushing Syndrome - physiopathology ; Cushing Syndrome - psychology ; Developmental Disabilities - etiology ; Developmental Disabilities - physiopathology ; Endocrinology &amp; Metabolism ; Enzymes ; Feedback, Physiological ; Female ; Fetus - physiology ; Fetuses ; Glucocorticoids ; Glucocorticoids - adverse effects ; Glucocorticoids - physiology ; Humans ; Hypothalamic-pituitary-adrenal axis ; Hypothalamo-Hypophyseal System - physiopathology ; Hypothalamus ; Infant, Low Birth Weight ; Infant, Newborn ; Infant, Small for Gestational Age ; Maternal-Fetal Exchange ; Metabolic syndrome ; Metabolic Syndrome - embryology ; Metabolic Syndrome - etiology ; Metabolic Syndrome - physiopathology ; Metabolism ; Models, Biological ; Neuroendocrinology ; Neuropsychology ; Pituitary-Adrenal System - physiopathology ; Placenta ; Placenta - enzymology ; Pregnancy ; Pregnancy Complications - physiopathology ; Pregnancy Complications - psychology ; Prenatal Exposure Delayed Effects ; Progeny ; Programming ; Psychiatry ; Stress, Physiological - physiology ; Stress, Psychological - physiopathology</subject><ispartof>Psychoneuroendocrinology, 2013-01, Vol.38 (1), p.1-11</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-13cafec02d73d166c83f27ed89ba994d481e690fcb4a097d620a4936405f3ffd3</citedby><cites>FETCH-LOGICAL-c490t-13cafec02d73d166c83f27ed89ba994d481e690fcb4a097d620a4936405f3ffd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22998948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reynolds, Rebecca M</creatorcontrib><title>Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis – 2012 Curt Richter Award Winner</title><title>Psychoneuroendocrinology</title><addtitle>Psychoneuroendocrinology</addtitle><description>Summary Low birthweight, a marker of an adverse in utero environment, is associated with cardiometabolic disease and brain disorders in adulthood. The adaptive changes made by the fetus in response to the intra-uterine environment result in permanent changes in physiology, structure and metabolism, a phenomenon termed early life programming. One of the key hypotheses to explain programming, namely over exposure of the developing fetus to glucocorticoids, was proposed nearly two decades ago, following the observation that the fetus was protected from high glucocorticoid levels in the mother by the actions of the placental barrier enzyme, 11β-hydroxysteroid dehydrogenase, which converts active glucocorticoids into inactive products. Numerous mechanistic studies in animal models have been carried out to test this hypothesis using manipulations to increase maternal glucocorticoids. Overall, these have resulted in offspring of lower birthweight, with an activated hypothalamic–pituitary–adrenal (HPA) axis and an adverse metabolic profile and behavioural phenotype in adulthood. Altered glucocorticoid activity or action is a good candidate mechanism in humans to link low birthweight with cardiometabolic and brain disorders. We have carried out detailed studies in men and women showing that high levels of endogenous glucocorticoids, or treatment with exogenous glucocorticoids, is associated with an adverse metabolic profile, increased cardiovascular disease and altered mood and cognitive decline. Our laboratory carried out the first translational studies in humans to test the glucocorticoid hypothesis, firstly demonstrating in studies of adult men and women, that low birthweight was associated with high fasting cortisol levels. We went on to dissect the mechanisms underlying the high fasting cortisol, demonstrating activation of the HPA axis, with increased cortisol responses to stimulation with exogenous adrenocorticotrophin hormone, lack of habituation to the stress of venepuncture, and increased cortisol responses to psychosocial stress. We have developed new dynamic tests to dissect the mechanisms regulating HPA axis central negative feedback sensitivity in humans, and demonstrated that this may be altered in obesity, one component of the metabolic syndrome. There are now studies in humans demonstrating that high circulating levels of maternal cortisol during pregnancy correlate negatively with birthweight, suggesting that excess glucocorticoids can by-pass the placental barrier. Deficiencies in the barrier enzyme, potentially increasing fetal glucocorticoid exposure, can also arise in association with maternal stress, malnutrition and disease, and can be inhibited by consumption of liquorice, which contains glycyrrhizin, an HSD inhibitor. Importantly, studies in humans have now demonstrated that high maternal cortisol in pregnancy and/or inhibition of HSD2 are associated with programmed outcomes in childhood including higher blood pressure, behavioural disorders as well as altered brain structure. We are investigating this further, using novel magnetic resonance imaging techniques to study the developing fetal brain in utero. The translational studies in support of the glucocorticoid hypothesis, and demonstrating that glucocorticoids are both mediators and targets of programming, are exciting and raise the question of whether this information can be used to identify those individuals most at risk of later life disease. In a recent study we showed that alterations in DNA methylation at genes important in regulating cortisol levels, tissue glucocorticoid action, blood pressure and fetal growth, are present in adulthood in association with both early life parameters and cardiometabolic risk factors. These preliminary data add to the limited literature in humans indicating a persisting epigenetic link between early life events and subsequent disease risk. Such findings open novel avenues for further exploration of the contribution of glucocorticoids to later life disease.</description><subject>11 beta -Hydroxysteroid dehydrogenase</subject><subject>11-beta-Hydroxysteroid Dehydrogenase Type 2 - antagonists &amp; inhibitors</subject><subject>11-beta-Hydroxysteroid Dehydrogenase Type 2 - physiology</subject><subject>Adaptation, Physiological</subject><subject>Adult</subject><subject>Animal models</subject><subject>Animals</subject><subject>Awards and Prizes</subject><subject>Birth weight</subject><subject>Birthweight</subject><subject>Brain</subject><subject>Brain Diseases, Metabolic - embryology</subject><subject>Brain Diseases, Metabolic - etiology</subject><subject>Brain Diseases, Metabolic - physiopathology</subject><subject>Cardiovascular Diseases - embryology</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - physiopathology</subject><subject>Cognition Disorders - etiology</subject><subject>Cognition Disorders - physiopathology</subject><subject>Cognitive decline</subject><subject>Cushing Syndrome - embryology</subject><subject>Cushing Syndrome - physiopathology</subject><subject>Cushing Syndrome - psychology</subject><subject>Developmental Disabilities - etiology</subject><subject>Developmental Disabilities - physiopathology</subject><subject>Endocrinology &amp; Metabolism</subject><subject>Enzymes</subject><subject>Feedback, Physiological</subject><subject>Female</subject><subject>Fetus - physiology</subject><subject>Fetuses</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - adverse effects</subject><subject>Glucocorticoids - physiology</subject><subject>Humans</subject><subject>Hypothalamic-pituitary-adrenal axis</subject><subject>Hypothalamo-Hypophyseal System - physiopathology</subject><subject>Hypothalamus</subject><subject>Infant, Low Birth Weight</subject><subject>Infant, Newborn</subject><subject>Infant, Small for Gestational Age</subject><subject>Maternal-Fetal Exchange</subject><subject>Metabolic syndrome</subject><subject>Metabolic Syndrome - embryology</subject><subject>Metabolic Syndrome - etiology</subject><subject>Metabolic Syndrome - physiopathology</subject><subject>Metabolism</subject><subject>Models, Biological</subject><subject>Neuroendocrinology</subject><subject>Neuropsychology</subject><subject>Pituitary-Adrenal System - physiopathology</subject><subject>Placenta</subject><subject>Placenta - enzymology</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - physiopathology</subject><subject>Pregnancy Complications - psychology</subject><subject>Prenatal Exposure Delayed Effects</subject><subject>Progeny</subject><subject>Programming</subject><subject>Psychiatry</subject><subject>Stress, Physiological - physiology</subject><subject>Stress, Psychological - physiopathology</subject><issn>0306-4530</issn><issn>1873-3360</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkrtuFDEUhi0EIkvgFSKXNDv4Fo9NgYhWEJAiIUEQpeW1z2S9zNqDPZOwHSU9b8iT4MkmFDRUv2V9_7kjdEJJQwmVL7bNUPYRJogNI5Q1RDVVHqAFVS1fci7JQ7QgnMilOOXkCD0pZUsIkUqyx-iIMa2VFmqBfp73k0su5TG4FDyG7w5KwTZ6PG4Ae7iGPg07iKPtccrhKsSCU4d9KGALvMSXN6lSznq4_R-hjCFe3Zo3-yFVLaHg3z9-4blOvJryiD8Gtxkh47Mbmz3-EmKE_BQ96mxf4NmdHqPPb99crt4tLz6cv1-dXSyd0GRcUu5sB44w33JPpXSKd6wFr_Taai28UBSkJp1bC0t06yUjVmguBTnteNd5foyeH-IOOX2barVmF4qDvrcR0lQMZS1rhaRKVlQeUJdTKRk6M-Sws3lvKDHzFszW3G_BzN0ZokyVajy5yzGtd-D_2u7HXoHXBwBqp9cBsikuQHTgQwY3Gp_C_3O8-ieE60MMzvZfYQ9lm6Yc6xwNNaV6zKf5FuZToIzUJxf8D_ows6Y</recordid><startdate>201301</startdate><enddate>201301</enddate><creator>Reynolds, Rebecca M</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>201301</creationdate><title>Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis – 2012 Curt Richter Award Winner</title><author>Reynolds, Rebecca M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-13cafec02d73d166c83f27ed89ba994d481e690fcb4a097d620a4936405f3ffd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>11 beta -Hydroxysteroid dehydrogenase</topic><topic>11-beta-Hydroxysteroid Dehydrogenase Type 2 - antagonists &amp; inhibitors</topic><topic>11-beta-Hydroxysteroid Dehydrogenase Type 2 - physiology</topic><topic>Adaptation, Physiological</topic><topic>Adult</topic><topic>Animal models</topic><topic>Animals</topic><topic>Awards and Prizes</topic><topic>Birth weight</topic><topic>Birthweight</topic><topic>Brain</topic><topic>Brain Diseases, Metabolic - embryology</topic><topic>Brain Diseases, Metabolic - etiology</topic><topic>Brain Diseases, Metabolic - physiopathology</topic><topic>Cardiovascular Diseases - embryology</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - physiopathology</topic><topic>Cognition Disorders - etiology</topic><topic>Cognition Disorders - physiopathology</topic><topic>Cognitive decline</topic><topic>Cushing Syndrome - embryology</topic><topic>Cushing Syndrome - physiopathology</topic><topic>Cushing Syndrome - psychology</topic><topic>Developmental Disabilities - etiology</topic><topic>Developmental Disabilities - physiopathology</topic><topic>Endocrinology &amp; Metabolism</topic><topic>Enzymes</topic><topic>Feedback, Physiological</topic><topic>Female</topic><topic>Fetus - physiology</topic><topic>Fetuses</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - adverse effects</topic><topic>Glucocorticoids - physiology</topic><topic>Humans</topic><topic>Hypothalamic-pituitary-adrenal axis</topic><topic>Hypothalamo-Hypophyseal System - physiopathology</topic><topic>Hypothalamus</topic><topic>Infant, Low Birth Weight</topic><topic>Infant, Newborn</topic><topic>Infant, Small for Gestational Age</topic><topic>Maternal-Fetal Exchange</topic><topic>Metabolic syndrome</topic><topic>Metabolic Syndrome - embryology</topic><topic>Metabolic Syndrome - etiology</topic><topic>Metabolic Syndrome - physiopathology</topic><topic>Metabolism</topic><topic>Models, Biological</topic><topic>Neuroendocrinology</topic><topic>Neuropsychology</topic><topic>Pituitary-Adrenal System - physiopathology</topic><topic>Placenta</topic><topic>Placenta - enzymology</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - physiopathology</topic><topic>Pregnancy Complications - psychology</topic><topic>Prenatal Exposure Delayed Effects</topic><topic>Progeny</topic><topic>Programming</topic><topic>Psychiatry</topic><topic>Stress, Physiological - physiology</topic><topic>Stress, Psychological - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reynolds, Rebecca M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Psychoneuroendocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reynolds, Rebecca M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis – 2012 Curt Richter Award Winner</atitle><jtitle>Psychoneuroendocrinology</jtitle><addtitle>Psychoneuroendocrinology</addtitle><date>2013-01</date><risdate>2013</risdate><volume>38</volume><issue>1</issue><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>0306-4530</issn><eissn>1873-3360</eissn><abstract>Summary Low birthweight, a marker of an adverse in utero environment, is associated with cardiometabolic disease and brain disorders in adulthood. The adaptive changes made by the fetus in response to the intra-uterine environment result in permanent changes in physiology, structure and metabolism, a phenomenon termed early life programming. One of the key hypotheses to explain programming, namely over exposure of the developing fetus to glucocorticoids, was proposed nearly two decades ago, following the observation that the fetus was protected from high glucocorticoid levels in the mother by the actions of the placental barrier enzyme, 11β-hydroxysteroid dehydrogenase, which converts active glucocorticoids into inactive products. Numerous mechanistic studies in animal models have been carried out to test this hypothesis using manipulations to increase maternal glucocorticoids. Overall, these have resulted in offspring of lower birthweight, with an activated hypothalamic–pituitary–adrenal (HPA) axis and an adverse metabolic profile and behavioural phenotype in adulthood. Altered glucocorticoid activity or action is a good candidate mechanism in humans to link low birthweight with cardiometabolic and brain disorders. We have carried out detailed studies in men and women showing that high levels of endogenous glucocorticoids, or treatment with exogenous glucocorticoids, is associated with an adverse metabolic profile, increased cardiovascular disease and altered mood and cognitive decline. Our laboratory carried out the first translational studies in humans to test the glucocorticoid hypothesis, firstly demonstrating in studies of adult men and women, that low birthweight was associated with high fasting cortisol levels. We went on to dissect the mechanisms underlying the high fasting cortisol, demonstrating activation of the HPA axis, with increased cortisol responses to stimulation with exogenous adrenocorticotrophin hormone, lack of habituation to the stress of venepuncture, and increased cortisol responses to psychosocial stress. We have developed new dynamic tests to dissect the mechanisms regulating HPA axis central negative feedback sensitivity in humans, and demonstrated that this may be altered in obesity, one component of the metabolic syndrome. There are now studies in humans demonstrating that high circulating levels of maternal cortisol during pregnancy correlate negatively with birthweight, suggesting that excess glucocorticoids can by-pass the placental barrier. Deficiencies in the barrier enzyme, potentially increasing fetal glucocorticoid exposure, can also arise in association with maternal stress, malnutrition and disease, and can be inhibited by consumption of liquorice, which contains glycyrrhizin, an HSD inhibitor. Importantly, studies in humans have now demonstrated that high maternal cortisol in pregnancy and/or inhibition of HSD2 are associated with programmed outcomes in childhood including higher blood pressure, behavioural disorders as well as altered brain structure. We are investigating this further, using novel magnetic resonance imaging techniques to study the developing fetal brain in utero. The translational studies in support of the glucocorticoid hypothesis, and demonstrating that glucocorticoids are both mediators and targets of programming, are exciting and raise the question of whether this information can be used to identify those individuals most at risk of later life disease. In a recent study we showed that alterations in DNA methylation at genes important in regulating cortisol levels, tissue glucocorticoid action, blood pressure and fetal growth, are present in adulthood in association with both early life parameters and cardiometabolic risk factors. These preliminary data add to the limited literature in humans indicating a persisting epigenetic link between early life events and subsequent disease risk. Such findings open novel avenues for further exploration of the contribution of glucocorticoids to later life disease.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>22998948</pmid><doi>10.1016/j.psyneuen.2012.08.012</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0306-4530
ispartof Psychoneuroendocrinology, 2013-01, Vol.38 (1), p.1-11
issn 0306-4530
1873-3360
language eng
recordid cdi_proquest_miscellaneous_1272746186
source ScienceDirect Freedom Collection 2022-2024
subjects 11 beta -Hydroxysteroid dehydrogenase
11-beta-Hydroxysteroid Dehydrogenase Type 2 - antagonists & inhibitors
11-beta-Hydroxysteroid Dehydrogenase Type 2 - physiology
Adaptation, Physiological
Adult
Animal models
Animals
Awards and Prizes
Birth weight
Birthweight
Brain
Brain Diseases, Metabolic - embryology
Brain Diseases, Metabolic - etiology
Brain Diseases, Metabolic - physiopathology
Cardiovascular Diseases - embryology
Cardiovascular Diseases - etiology
Cardiovascular Diseases - physiopathology
Cognition Disorders - etiology
Cognition Disorders - physiopathology
Cognitive decline
Cushing Syndrome - embryology
Cushing Syndrome - physiopathology
Cushing Syndrome - psychology
Developmental Disabilities - etiology
Developmental Disabilities - physiopathology
Endocrinology & Metabolism
Enzymes
Feedback, Physiological
Female
Fetus - physiology
Fetuses
Glucocorticoids
Glucocorticoids - adverse effects
Glucocorticoids - physiology
Humans
Hypothalamic-pituitary-adrenal axis
Hypothalamo-Hypophyseal System - physiopathology
Hypothalamus
Infant, Low Birth Weight
Infant, Newborn
Infant, Small for Gestational Age
Maternal-Fetal Exchange
Metabolic syndrome
Metabolic Syndrome - embryology
Metabolic Syndrome - etiology
Metabolic Syndrome - physiopathology
Metabolism
Models, Biological
Neuroendocrinology
Neuropsychology
Pituitary-Adrenal System - physiopathology
Placenta
Placenta - enzymology
Pregnancy
Pregnancy Complications - physiopathology
Pregnancy Complications - psychology
Prenatal Exposure Delayed Effects
Progeny
Programming
Psychiatry
Stress, Physiological - physiology
Stress, Psychological - physiopathology
title Glucocorticoid excess and the developmental origins of disease: Two decades of testing the hypothesis – 2012 Curt Richter Award Winner
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T13%3A22%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glucocorticoid%20excess%20and%20the%20developmental%20origins%20of%20disease:%20Two%20decades%20of%20testing%20the%20hypothesis%20%E2%80%93%202012%20Curt%20Richter%20Award%20Winner&rft.jtitle=Psychoneuroendocrinology&rft.au=Reynolds,%20Rebecca%20M&rft.date=2013-01&rft.volume=38&rft.issue=1&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=0306-4530&rft.eissn=1873-3360&rft_id=info:doi/10.1016/j.psyneuen.2012.08.012&rft_dat=%3Cproquest_cross%3E1272746186%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c490t-13cafec02d73d166c83f27ed89ba994d481e690fcb4a097d620a4936405f3ffd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1272746186&rft_id=info:pmid/22998948&rfr_iscdi=true